Outcomes of persons with blastomycosis involving the central nervous system

被引:27
作者
Bush, Jonathan W. [1 ]
Wuerz, Terry [2 ,3 ]
Embil, John M. [2 ,3 ]
Del Bigio, Marc R. [1 ]
McDonald, Patrick J. [4 ]
Krawitz, Sherry [1 ]
机构
[1] Univ Manitoba, Dept Pathol, Winnipeg, MB R3T 2N2, Canada
[2] Univ Manitoba, Dept Med, Infect Dis Sect, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada
[4] Univ Manitoba, Dept Surg, Neurosurg Sect, Winnipeg, MB R3T 2N2, Canada
关键词
Blastomycosis; Blastomyces dermatitidis; Central nervous system; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CEREBRAL BLASTOMYCOSIS; AMPHOTERICIN-B; RECURRENT BLASTOMYCOSIS; SURGICAL PATHOLOGY; FUNGAL-INFECTIONS; DERMATITIDIS; MENINGITIS; DIAGNOSIS; BRAIN;
D O I
10.1016/j.diagmicrobio.2013.03.002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Blastomyces dermatitidis is a dimorphic fungus which is potentially life-threatening if central nervous system (CNS) dissemination occurs. Sixteen patients with proven or probable CNS blastomycosis are presented. Median duration of symptoms was 90 days; headache and focal neurologic deficit were the most common presenting symptoms. Magnetic resonance imaging (MRI) consistently demonstrated an abnormality, compared to 58% of computed tomography scans. Tissue culture yielded the pathogen in 71% of histology-confirmed cases. All patients who completed treatment of an amphotericin B formulation and extended azole-based therapy did not relapse. Initial nonspecific symptoms lead to delayed diagnosis of CNS blastomycosis. A high index of suspicion is necessary if there is history of contact with an area where B. dermatitidis is endemic. Diagnostic tests should include MRI followed by biopsy for tissue culture and pathology. Optimal treatment utilizes a lipid-based amphotericin B preparation with an extended course of voriconazole. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 39 条
[1]   ISOLATION OF BLASTOMYCES-DERMATITIDIS FROM AN EARTHEN FLOOR IN SOUTHWESTERN ONTARIO, CANADA [J].
BAKERSPIGEL, A ;
KANE, J ;
SCHAUS, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 1986, 24 (05) :890-891
[2]   Successful treatment of cerebral blastomycosis with voriconazole [J].
Bakleh, M ;
Aksamit, AJ ;
Tleyjeh, IM ;
Marshall, WF .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) :E69-E71
[3]   Blastomycosis of the Central Nervous System: A Multicenter Review of Diagnosis and Treatment in the Modern Era [J].
Bariola, J. Ryan ;
Perry, Paul ;
Pappas, Peter G. ;
Proia, Laurie ;
Shealey, Wesley ;
Wright, Patty W. ;
Sizemore, James M. ;
Robinson, Matthew ;
Bradsher, Robert W., Jr. .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (06) :797-804
[4]   Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen [J].
Borgia, Sergio M. ;
Fuller, Jeffrey D. ;
Sarabia, Alicia ;
El-Helou, Philippe .
MEDICAL MYCOLOGY, 2006, 44 (07) :659-664
[5]  
Chander Bal, 2007, Indian J Pathol Microbiol, V50, P821
[6]   Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America [J].
Chapman, Stanley W. ;
Dismukes, William E. ;
Proia, Laurie A. ;
Bradsher, Robert W. ;
Pappas, Peter G. ;
Threlkeld, Michael G. ;
Kauffman, Carol A. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1801-1812
[7]   Recurrent blastomycosis of the central nervous system: Case report and review [J].
Chowfin, A ;
Tight, R ;
Mitchell, S .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (06) :969-971
[8]  
Cook PP, 2001, SOUTHERN MED J, V94, P548, DOI 10.1097/00007611-200105000-00026
[9]  
COOPER K, 1988, S AFR MED J, V74, P521
[10]   Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals [J].
Crampton, TL ;
Light, RB ;
Berg, GM ;
Meyers, MP ;
Schroeder, GC ;
Hershfield, ES ;
Embil, JM .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (10) :1310-1316